NCT05640778

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

Efficacy and Safety of Neoadjuvant Dalpiciclib Combined With Endocrine Therapy in Luminal B/HER2-negative Breast Cancer and Biomarker Analysis: a Single-arm, Open-label Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the efficacy and safety of Dalpiciclib combined with aromatase inhibitors as a neoadjuvant therapy in Luminal B/HER2-negative breast cancer.

Conditions

• Luminal B/HER2-negative Breast Cancer

Interventions

Type	Name	Description
DRUG	Dalpiciclib combined with aromatase inhibitors	Dalpiciclib combined with letrozole or anastrozole

Timeline

• Start date: 2022-10-01
• Primary completion: 2024-10-31
• Completion: 2025-10-31
• First posted: 2022-12-07
• Last updated: 2024-01-31

Locations

1 site across 1 country: China